Top Markets
#1 Islamic Coin Islamic Coin +151.57%
#2 Black Phoenix Black Phoenix +35.20%
#3 Velvet Velvet +24.01%
#4 Akedo Akedo +19.95%
#5 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +19.32%
#6 Fake World Assets Fake World Assets +16.68%
#7 DoubleZero DoubleZero +13.22%
#8 HOME HOME +12.52%
#9 clBTC clBTC +11.84%
#10 Not in Employment, Education, or Training Not in Employment, Education, or Training +11.39%
Coin of the day
Islamic Coin Islamic Coin
Settings
Language
ENGLISH
Currency
USD
Theme
Bioasis Technologies Inc. Bioasis Technologies Inc.

Bioasis Technologies Inc.

BTI
Rank in Stocks #39944
Bioasis Technologies Inc. is a development-stage biopharmaceutical firm focused... Bioasis Technologies Inc. is a development-stage biopharmaceutical firm focused on innovating diagnostic methods and therapeutic solutions for a range of neurological conditions. The company's primary technological asset is the xB3 platform, engineered to enable the transport of medicinal compounds across the often-impenetrable blood-brain barrier. This capability is crucial for addressing central nervous system disorders, including various brain cancers, metabolic dysfunctions, and neurodegenerative illnesses. Bioasis is actively advancing its in-house pipeline with programs such as xB3-001 for brain metastases, xB3-002 for glioblastoma, and xB3-007 for neurodegenerative diseases, all designed to offer both symptomatic relief and disease-modifying benefits. The company has also established numerous strategic alliances. These include a partnership with Aposense Limited to deliver siRNA therapeutics for CNS disorders; a collaboration with Oxyrane UK Ltd. to combine the xB3 technology with Oxyrane's OxyCAT platform for enhanced enzyme replacement therapy targeting the brain; an agreement with Janssen Biotech, Inc. for the discovery, development, and commercialization of novel products leveraging the xB3 platform; and a research and licensing deal with Neuramedy Co Ltd. to develop and market an xB3-enhanced version of their antibody, Tomaralimab. Founded in 2006, Bioasis Technologies Inc. is headquartered in New Haven, Connecticut.
Share Price
$0.00366968
Last synced: 2024-07-23
Market Cap
$291.42K
Change (1 day)
-0.81%
Change (1 year)
0.00%
Country
US
Trade Bioasis Technologies Inc. (BTI)

Category

Healthcare
Operating Margin for Bioasis Technologies Inc. (BTI)
Operating Margin as of 2026 TTM: 0.00%
According to Bioasis Technologies Inc. latest financial reports and stock price the company's current Operating Margin (TTM) is 0.00%. At the end of 2026 the company had an Operating Margin of 0.00%.
Operating Margin history for Bioasis Technologies Inc. from 2026 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
Not enough data for the provided dates.
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
38.97% -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
28.81% -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00% -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
0.00% -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
31.23% -
BE
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.